Clinical Trial Update: Efficacy and Safety of Bevacizumab/Temsirolimus Combination to Treat Advanced Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of bevacizumab and temsirolimus for advanced renal cell carcinoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Temsirolimus (temsirolimus)

Snippet

Sponsor: Hellenic Cooperative Oncology Group | Conditions: Kidney Cancer | Phase 2 | Status: TERMINATED